Triple Helix Chapter South Asia Pakistan





Head quartered at University of Management and Technology Lahore Pakistan

www.triplehelixsouthasia.pk

Leading Business Transformation in Pakistan






Classical Triple Helix Model

Triple Helix of University-Industry-Government Relations,

Fig. 1 A triple helix configuration with negative and positive overlap among the three subsystems



Global Competitiveness Index

122


Global Innovation Index	119
Innovation input	123
Innovation output	108

Etzkowitz, H. and Leydesdorff, L. (2000). 'The dynamics of innovation: from National Systems and "Mode 2" to a Triple Helix of university—industry—government relations', *Research Policy*, Vol 29, pp 109–123.

<u>Biopharma</u>


Global Value
Chain Flows –
Mapping
ownership and
supply
relationships of the
top 20508 firms
that participate in
the Biopharma
GVC

Number	Cluster
11	Biopharma R&D
12	Biopharma R&D & manufacturing
13	Biopharma R&D & services diversified
14	Clinical research & human health activities
21	Bio-pharma manufacturing
22	Biopharma manufacturing and wholesale
23	Perfumes and cosmetics manufacturing
24	Biopharma manufacturing multi-diversified
25	Chemical & biopharma manufacturing diversified
26	Medical instruments, dental & electrotherapeutic manufacturing
27	Manufactured goods, electronics and instruments
28	Special purpose machinery and equipment
31	Specialised biopharma wholesale
32	Biopharma retail
33	Biopharma & cosmetics wholesale
34	Pharma wholesale trade & services diversified
35	Chemical & biopharma wholesale
36	Medical & hospital equipment wholesale & supplies
41	Holding, financial & administrative head office services
42	Other business and management services
43	Finance & insurance services
44	Miscellaneous services
51	Agriculture, food processing & drinks of bio products
52	Manufactured miscellaneous goods
53	Electricity, gas and water supply & services
54	Other miscellaneous wholesale




- © Todeva / Bell
 - Biopharma is the fastest growing sector in Europe, attracting the largest proportion of investment, with 77 multinational firms and 6505 operating establishments
 - The average R&D investment by the parents is over €53 mln (2013) with average profits of €49 mln (2013) and revenue from sales over €512 mln (2013)
 - Biopharma GVC is entangled in finance, business and management services, and wholesale, retail, trade services that secure financing of the R&D and the manufacturing operations
 - There is simultaneously increasing specialization within firms, and new emergent diversification portfolios
 - The GVC is pulled by the output markets, including pharma wholesale and retail (31, 32), cosmetics (23), medical instruments, dental, hospital and electro-therapeutic manufacturing (26) and agro-food, drinks and bio-products (51)
 - Innovation from all other sectors is integrated in the biopharma GVC, including chemicals, plastics, eco-bio products, miscellaneous products, miscellaneous services, medical and hospital services

Global Biopharma (20508 firms)



From Knowledge to Practice











HOME ABOUT THE SUMMIT ▼ CALL FOR PAPERS SPONSORSHIP & EXHIBITION REGISTRATION SPEAKERS & PROGRAMMES ▼ VENUE, HOTELS & FLIGHTS

